Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Tracking Brain Changes During Real and Imagined Movements in People With ALS (Lou Gehrig's Disease) and Healthy Volunteers.
The purpose of this study is to track areas of the brain, via functional magnetic resonance imaging (fMRI), that retain structural and functional integrity throughout the lifespan of people with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
A severe physical disability has a dramatic impact on a person's life, whether it is caused
by a neuro-degenerative disease such as amyotrophic lateral sclerosis (ALS), a brainstem
stroke, or a spinal cord injury. Someone with these conditions may be effectively
"locked-in," retaining their cognitive ability, but unable to perform any movement except,
possibly, the most basic eye movements.
Areas of the brain that retain structural and functional integrity throughout the lifespan
of people with ALS may be suitable for a technology called brain-computer interfaces (BCI).
One day, BCIs—which can be operated "just by thinking"—may allow people with neurological
disorders, such as ALS, to communicate and regain some mobility with the assistance of
electronic devices.
In this study we will use functional magnetic resonance imaging (fMRI) to track areas of the
brain that retain structural and functional integrity throughout the lifespan of people with
ALS.
The trial involves visits to the study facility every 2-6 months for up to 30 months or
until visits are no longer possible. During each visit, participants will undergo a fMRI
exam. During that time they will view visual images and be asked to perform 4 different
motor tasks: 1) actual finger tapping, 2) actual fist clenching, 3) imaginary finger
tapping, and 4) imaginary fist clenching. Each of the mini-experiments (tasks) lasts for
about 6-7 minutes. While the participants are performing the tasks their brains will be
repeatedly imaged using fMRI. We will then use the images to look for correlations to the
tasks, which in turn will result in identifying the brain areas responsible for the
activities. After the fMRI, participants will be asked to fill out questionnaires.
Performing the tasks takes about 90 minutes and filling out the questionnaires takes about
30 minutes.
The facility is located on the North Campus of the University of Michigan-Ann Arbor. The
study coordinators currently are enrolling participants with ALS and creating a database of
healthy volunteers whom they will contact at a later date.
Information gained from this study will contribute to a better understanding of ALS disease
progression, and could lead to significant quality-of-life improvements for persons with
end-stage ALS.
;
Observational Model: Case Control
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |